1188335-21-8

Basic information

• Product Name: (6S)-6-[(4-bromo-2-fluorobenzyl)oxy]-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
• Synonyms: (6S)-6-[(4-bromo-2-fluorobenzyl)oxy]-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine
• CAS NO: 1188335-21-8
• Molecular Weight: 372.15
• Mol File: 1188335-21-8.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: (6S)-6-[(4-bromo-2-fluorobenzyl)oxy]-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine(CAS DataBase Reference)
• NIST Chemistry Reference: (6S)-6-[(4-bromo-2-fluorobenzyl)oxy]-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine(1188335-21-8)
• EPA Substance Registry System: (6S)-6-[(4-bromo-2-fluorobenzyl)oxy]-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine(1188335-21-8)

Safety Data

• Hazardous Substances Data: 1188335-21-8(Hazardous Substances Data)

Upstream product

• 187235-08-1 (S)‐2‐nitro‐6,7‐dihydro‐5H‐imidazo[2,1‐b][1,3]oxazin‐6‐ol 
• 76283-09-5 4-bromo-2-fluorobenzyl bromide 

Downstream Products

• 1188918-38-8 C₂₅H₂₃F₂N₅O₇ 
• 1263417-08-8 (6S)-6-({2-fluoro-4-[5-(trifluoromethyl)-2-pyridinyl]benzyl}oxy)-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 
• 1263417-20-4 ⁽⁶⁵⁾-6-{[2-fluoro-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl]oxy}-2-nitro-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine 
• 1263417-06-6 (6S)-6-{[3-fluoro-4'-(trifluoromethoxy)[1,1'-biphenyl]-4-yl]methoxy}-2-nitro-6,7-dihydro-5H-imidazo[2,1-6][1,3]oxazine 

Relevant articles and documents

Biarylmethoxy 2-nitroimidazooxazine antituberculosis agents: Effects of proximal ring substitution and linker reversal on metabolism and efficacy

Abstract Certain biaryl analogues of antitubercular drug PA-824 displayed enhanced in vivo efficacies yet retained some susceptibility towards oxidative metabolism; therefore, two new strategies were explored to address this. Ortho-substitution of the pro

NITROIMIDAZOOXAZINES AND THEIR USES IN ANTI-TUBERCULAR THERAPY

The present invention relates to novel nitroimidazooxazines, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.